PHAXIAM Therapeutics S.A. (PHXM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
PHAXIAM Therapeutics S.A. stock (PHXM) is currently trading at $3.10. WallStSmart rates PHXM as Sell.
- PHXM PE ratio analysis and historical PE chart
- PHXM PS ratio (Price-to-Sales) history and trend
- PHXM intrinsic value — DCF, Graham Number, EPV models
- PHXM stock price prediction 2025 2026 2027 2028 2029 2030
- PHXM fair value vs current price
- PHXM insider transactions and insider buying
- Is PHXM undervalued or overvalued?
- PHAXIAM Therapeutics S.A. financial analysis — revenue, earnings, cash flow
- PHXM Piotroski F-Score and Altman Z-Score
- PHXM analyst price target and Smart Rating
PHAXIAM Therapeutics S.A.
📊 No data available
Try selecting a different time range
Smart Analysis
PHAXIAM Therapeutics S.A. (PHXM) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
PHAXIAM Therapeutics S.A. (PHXM) Key Strengths (0)
PHAXIAM Therapeutics S.A. (PHXM) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -66.40%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 0.00%
Micro-cap company with very limited liquidity and high volatility
PHAXIAM Therapeutics S.A. (PHXM) Detailed Analysis Report
Overall Assessment
This company scores 4/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -66.40%, which may limit upside. Profitability pressure is visible in Return on Equity at -38.60%, Operating Margin at -3232.00%, Profit Margin at -191.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -38.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -66.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PHXM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for PHAXIAM Therapeutics S.A. (PHXM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
PHAXIAM Therapeutics S.A. is in a turnaround phase, with management focused on restoring profitability. Revenue reached 6M with 66% decline year-over-year. The company is currently unprofitable, posting a -191.0% profit margin.
Key Findings
Spending 117% of revenue (7M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 66% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -191.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.96, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact PHAXIAM Therapeutics S.A..
Bottom Line
PHAXIAM Therapeutics S.A. is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About PHAXIAM Therapeutics S.A.(PHXM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company is headquartered in Lyon, France.